On sensitivity analysis using a random‐effects model ( Table S2 ), the treatment benefit of FCM on the composite endpoint of recurrent heart failure hospitalization and cardiovascular death (RR = 0.68; 95% CI = 0.47–1.00; I 2 = 54%), and time to first HF hospitalization or cardiovascular death (RR = 0.70; 95% CI = 0.50–1.00; I 2 = 55%) became borderline significant.
← all excerpts
Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis.
1
—
—